Livzon Pharmaceutical : Overseas Regulatory Announcement

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Overseas Regulatory Announcement

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

Set out below is the "ANNOUNCEMENT ON RECEIPT OF A DRUG MANUFACTURING CERTIFICATE" of Livzon Pharmaceutical Group Inc.＊ published on the website of the Shenzhen Stock Exchange, which is set out herein for information purpose only.

The abovementioned announcement is prepared in Chinese, if there is any discrepancy between the Chinese version and the English version, the Chinese version shall prevail.

By order of the Board

Livzon Pharmaceutical Group Inc. ＊

麗珠醫藥集團股份有限公司

Yang Liang

Company Secretary

Zhuhai, China

23 September 2020

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

* For identification purpose only

Stock code: 000513, 01513

Stock abbreviation: Livzon Group, Livzon Pharma

Announcement No.: 2020-098

LIVZON PHARMACEUTICAL GROUP INC.

ANNOUNCEMENT ON RECEIPT OF

A DRUG MANUFACTURING CERTIFICATE

The Company and all members of the Board of Directors guarantee all contents of the disclosed information are true, accurate and complete, and no false representation, misleading statement or material omission is made.

Recently, 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the "Company") received a Drug Manufacturing Certificate issued by the Drug Administration of Guangdong Province, which approved the Company, as the marketing authorization holder, to apply for the registration of Voriconazole for Injection (0.2g), and approved Livzon Group Livzon Pharmaceutical Factory* (麗珠集 團麗珠製藥廠 ), a wholly-owned subsidiary of the Company, as the entrusted manufacturer to produce the above-mentioned drug. The details are as follows:

I. Basic Information of the Drug Manufacturing Certificate

Enterprise name: Livzon Pharmaceutical Group Inc.*

Certificate no.: Yue 20200702

Classification code: Bh

Registered address: Headquarters Building, 38 Chuangye North Road, Jinwan District, Zhuhai City

Issuing authority: Drug Administration of Guangdong Province

Expiry date: 17 September 2025

Site and scope of manufacturing: the entrusted party is Livzon Group Livzon Pharmaceutical Factory*, whose manufacturing site is located at 38 Chuangye North Road, Jinwan District, Zhuhai City. The entrusted product is Voriconazole for Injection.

II. The Impact on the Company

The receipt of the Drug Manufacturing Certificate is helpful for the Company to integrate and allocate the production resources of its subordinated enterprises, improve the utilization rate of its production capacity, reduce production costs and continuously improve the lifecycle quality management of its drugs. The receipt of the Drug Manufacturing Certificate has no significant impact on the Company's performance in the current period.

1. Risk Warning

Due to the characteristics of the pharmaceutical industry, the production and sale of pharmaceutical products are vulnerable to changes in market environment and involve uncertainties. Investors are requested to make decisions prudently and be aware of investment risks.

Notice is hereby given.

Board of Directors of Livzon Pharmaceutical Group Inc. *

24 September 2020

* For identification purpose only